Intervention strategies for microbial therapeutics in cancer immunotherapy [0.03%]
癌症免疫治疗中微生物疗法的干预策略
V Gopalakrishnan,B Weiner,C B Ford et al.
V Gopalakrishnan et al.
Immunotherapies have drastically improved clinical outcomes in a wide range of malignancies. Nevertheless, patient responses remain highly variable, and reliable biomarkers that predict responses accurately are not yet fully understood. Com...
Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry [0.03%]
计算机图像分析算法在PD-L1免疫组化评分中的应用及研究
L J Inge,E Dennis
L J Inge
Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have rapidly become integral to standard-of-care therapy for non-small cell lung cancer and other cancers. Immunohistochemical ...
Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors [0.03%]
多梳抑制复合物2突变可预测免疫检查点抑制剂治疗晚期癌症患者的生存获益
P J Vlachostergios
P J Vlachostergios
Background: Numerous biomarkers are being tested to enhance the ability of clinicians to predict responses and prognosis after treatment with immune checkpoint inhibitors (ICIs). Polycomb repressive complex 2 (PRC2) is a ...
1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs [0.03%]
1,2,3,MHC：基于质谱的相对和绝对定量PMHC免疫肽组方法综述
L E Stopfer,A D D&#x;Souza,F M White
L E Stopfer
Quantitative mass-spectrometry-based methods to perform relative and absolute quantification of peptides in the immunopeptidome are growing in popularity as researchers aim to measure the dynamic nature of the peptide major histocompatibili...
[This corrects the article DOI: 10.1016/j.iotech.2019.11.003.][This corrects the article DOI: 10.1016/j.iotech.2021.100034.][This corrects the article DOI: 10.1016/j.iotech.2020.03.001.][This corrects the article DOI: 10.1016/j.iotech.2019....
Published Erratum
Immuno-oncology technology. 2021 Nov 12:11:100051. DOI:10.1016/j.iotech.2021.100051 2021
The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens [0.03%]
功能遗传筛查发现肿瘤固有的免疫敏感决定因素
D W Vredevoogd,G Apriamashvili,D S Peeper
D W Vredevoogd
Functional genetic screens by CRISPR-Cas9 allow for the unbiased discovery of proteins causally involved in complex biological processes. In recent years, this approach has been used by multiple laboratories to uncover a range of tumor cell...
Z Bodalal,I Wamelink,S Trebeschi et al.
Z Bodalal et al.
With the ongoing advances in imaging techniques, increasing volumes of anatomical and functional data are being generated as part of the routine clinical workflow. This surge of available imaging data coincides with increasing research in q...
S Peters,J Tabernero,A Cervantes et al.
S Peters et al.
Germline genetic host factors as predictive biomarkers in immuno-oncology [0.03%]
免疫肿瘤学中作为预测生物标志物的生殖系遗传宿主因素
Vylyny Chat,Robert Ferguson,Tomas Kirchhoff
Vylyny Chat
In immuno-oncology (IO), the baseline host factors attract significant clinical interest as promising predictive biomarker candidates. Growing evidence from experimental or population-based studies suggests that the host genetic factors con...
Qian Chen,Tianyuan Ci,Zhen Gu
Qian Chen
Background: Surgery remains the first option to treat most solid tumors. However, despite the development of surgical techniques, the elimination of tumor recurrence after surgery remains a challenge. ...